We believe GENinCode is making strong strategic progress and see recent announcements building momentum within the company. We particularly note the commercial partnership with Thermo Fisher, which will see the multinational company support the uptake of GENinCode’s CARDIO inCode test in the US and EMEA regions. This follows further clinical evidence supporting the utility of the test, published in the Journal of the American College of Cardiology (JACC): Advances, adding to the growing body of ....
